Alpha Cancer Technologies Inc.

Innovative targeted chemotherapy delivery platform for the treatment of cancer. The dual benefit of little to no toxicity and greater efficacy for patients.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Toronto, Ontario, Canada
  • Currency CAD
  • Founded 2009
  • Employees 6
  • Website alpha-cancer.com

Company Summary

Alpha Cancer Technologies (ACT) has exclusive worldwide rights to Alpha Fetoprotein (AFP) a protein that targets cancer. ACT has the benefit of over $100 million spent on development including ~20 international patents, existing Drug Master File with the FDA - manufacturing, toxicology and human safety in 400+ patients from Phase I and II clinical trials. ACT has a significantly mitigated risk profile and an expedited clinical development path.

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free